[1]
Tha├ži, D., Armstrong, A., Lebwohl, M., Blauvelt, A., Paul, C., Puig, L., Wang, M., Vanvoorden, V., Madden, C., Wiegratz, S., Deherder, D. and Gordon, K. 2022. Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s71. DOI:https://doi.org/10.25251/skin.6.supp.71.